Q2 EPS Forecast for TScan Therapeutics Lowered by Analyst

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Research analysts at HC Wainwright reduced their Q2 2025 earnings estimates for TScan Therapeutics in a research note issued to investors on Thursday, March 6th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.32) per share for the quarter, down from their previous forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.30) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.30) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million.

Several other brokerages have also weighed in on TCRX. Barclays dropped their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Wedbush reissued an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reduced their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $9.20.

TScan Therapeutics Stock Performance

Shares of TCRX opened at $1.82 on Monday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a fifty day simple moving average of $2.36 and a 200 day simple moving average of $3.93. TScan Therapeutics has a 12 month low of $1.71 and a 12 month high of $9.69. The stock has a market capitalization of $97.14 million, a price-to-earnings ratio of -1.72 and a beta of 0.91.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TCRX. China Universal Asset Management Co. Ltd. bought a new stake in shares of TScan Therapeutics in the 4th quarter valued at $32,000. Prudential Financial Inc. purchased a new position in TScan Therapeutics during the 4th quarter worth $32,000. ProShare Advisors LLC purchased a new position in TScan Therapeutics during the 4th quarter worth $40,000. Wells Fargo & Company MN boosted its holdings in shares of TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after buying an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics in the 4th quarter worth about $59,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.